Description
The debate revealed that multiple redundant anti-ferroptosis systems exist, yet motor neurons still undergo ferroptotic death. Understanding which compensatory mechanisms are disrupted and why could identify more effective therapeutic targets than GPX4 alone.
Source: Debate session ds-SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed (Analysis: SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed)
Resolution criteria
Resolved when an evidence artifact identifies why GPX4-independent ferroptosis protection pathways fail to compensate in ALS motor neurons, with one of: (1) comparative biochemistry in ALS patient-derived motor neurons versus control neurons, measuring FSP1/AIFM2/GCH1 expression (qPCR, Western blot), GCH1 BH4 synthesis flux (stable isotope metabolomics), and ferroptosis sensitivity (RSL3 IC50 with or without FSP1/AIFM2 overexpression), establishing whether the compensation failure is due to low expression, low activity, or active inhibition of the backup pathways; (2) metabolomics profiling of lipid peroxidation products (4-HNE, MDA, F2-isoprostanes) in ALS spinal cord tissue versus controls, showing >=2-fold elevated lipid peroxidation despite normal GPX4 and FSP1 levels, with rescue by BH4 supplementation or FSP1 overexpression in patient motor neurons in vitro; (3) genome-wide CRISPR screen in motor neurons for ferroptosis sensitizers, identifying >=5 genes whose loss phenocopies the ALS motor neuron ferroptosis sensitivity phenotype, with >=2 validated as acting upstream of or parallel to GPX4-independent pathways.
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:29.867806+00:00”, “resolution_summary”: “Resolved by hypothesis h-3156f6bcd349: GPX4 reserve failure gates selective ALS motor-neuron ferroptosis. Supporting evidence includes debate sess_SDA-2026-04-18-gap-debate-20260417-032952-48bdcbea.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-3156f6bcd349”, “title”: “GPX4 reserve failure gates selective ALS motor-neuron ferroptosis”, “score”: 0.501, “reason”: “10 token overlaps; entity overlap: als, gpx4”, “analysis_id”: “SDA-2026-04-26-gap-ferroptosis-mnd-768eaeba1be3”, “target_gene”: “GPX4”, “target_pathway”: “ferroptosis”, “disease”: “neurodegeneration”, “composite_score”: 0.745, “confidence_score”: 0.72, “status”: “proposed”, “pubmed_evidence_ids”: [“29916020”, “31185581”, “38891021”, “38967083”, “38989463”]}, {“id”: “h-dd53a5c2”, “title”: “GCH1/BH4 Axis Stabilization for Dual Ferroptosis and Mitochondrial Protection”, “score”: 0.394, “reason”: “21 token overlaps; entity overlap: bh4, gch1”, “analysis_id”: “SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed”, “target_gene”: “GCH1, BH4”, “target_pathway”: null, “disease”: null, “composite_score”: 0.56, “confidence_score”: 0.56, “status”: “proposed”, “pubmed_evidence_ids”: [“29534603”, “30042732”, “30898788”, “31498569”, “31756067”]}, {“id”: “h-a01166ee”, “title”: “BH4 Cofactor Restoration as Primary Driver of >500-Fold Dopamine Elevation”, “score”: 0.346, “reason”: “19 token overlaps; entity overlap: bh4, gch1”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-145531-5c4e7b59”, “target_gene”: “GCH1, TH, BH4 pathway”, “target_pathway”: “Tetrahydrobiopterin synthesis / dopamine metabolism”, “disease”: “neurodegeneration”, “composite_score”: 0.618, “confidence_score”: 0.45, “status”: “proposed”, “pubmed_evidence_ids”: [“17270157”, “27491309”, “34876467”, “37214873”]}, {“id”: “h-e91a4dd06a”, “title”: “FSP1/CoQ10 Axis as GPX4-Independent Neuroprotective Pathway”, “score”: 0.328, “reason”: “4 token overlaps; entity overlap: fsp1, gpx4-”, “analysis_id”: “SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate”, “target_gene”: “FSP1 (NQO1/FDXR axis) / CoQ10 biosynthetic pathway”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.48, “confidence_score”: 0.55, “status”: “proposed”, “pubmed_evidence_ids”: [“31511692”, “31511695”, “37410468”]}, {“id”: “h-d2d37a81eeaa”, “title”: “ACSL4 lipid remodeling creates ferroptosis-prone ALS membranes”, “score”: 0.25, “reason”: “5 token overlaps; entity overlap: als”, “analysis_id”: “SDA-2026-04-26-gap-ferroptosis-mnd-768eaeba1be3”, “target_gene”: “ACSL4”, “target_pathway”: “PUFA phospholipid remodeling”, “disease”: “neurodegeneration”, “composite_score”: 0.7100000000000001, “confidence_score”: 0.685, “status”: “proposed”, “pubmed_evidence_ids”: [“29916020”, “31185581”, “38891021”, “38967083”, “38989463”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-18-gap-debate-20260417-032952-48bdcbea”, “title”: “The debate highlighted compelling correlative evidence for ferroptosis markers in ALS tissues, but causality remains unestablished. This fundamental question determines whether ferroptosis represents a viable therapeutic target or merely a downstream consequence of other pathological processes.\n\nSource: Debate session ds-SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed (Analysis: SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed)”, “score”: 0.494, “reason”: “9 token overlaps; entity overlap: als, sda-2026-04-16-”, “analysis_id”: “SDA-2026-04-18-gap-debate-20260417-032952-48bdcbea”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “ds-SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed”, “title”: “Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron chelation therapies”, “score”: 0.435, “reason”: “4 token overlaps; entity overlap: als, gpx4”, “analysis_id”: “SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed”, “quality_score”: 0.5885714285714286, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-26-gap-ferroptosis-mnd-768eaeba1be3_task-aa724961”, “title”: “What is the role of GPX4-dependent ferroptosis, lipid peroxidation, and iron handling in ALS and motor neuron disease?”, “score”: 0.418, “reason”: “4 token overlaps; entity overlap: als, gpx4-”, “analysis_id”: “SDA-2026-04-26-gap-ferroptosis-mnd-768eaeba1be3”, “quality_score”: 0.78, “status”: “completed”, “target_artifact_id”: “gap-ferroptosis-mnd-768eaeba1be3”, “target_artifact_type”: “knowledge_gap”}, {“id”: “sess_SDA-2026-04-15-gap-debate-20260410-112528-782f5aa2”, “title”: “While ACSL4-driven ferroptosis was strongly supported, the molecular triggers that tip the balance from protective GPX4 activity to pathological ACSL4-mediated vulnerability remain unclear. This balance point could be a critical therapeutic target.\n\nSource: Debate session sess_SDA-2026-04-02-gap-seaad-v4-20260402065846 (Analysis: SDA-2026-04-02-gap-seaad-v4-20260402065846)”, “score”: 0.336, “reason”: “7 token overlaps; entity overlap: gpx4”, “analysis_id”: “SDA-2026-04-15-gap-debate-20260410-112528-782f5aa2”, “quality_score”: 0.8, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-23-gap-debate-20260417-033119-54941818_task_9aae8fc5”, “title”: “The debate highlighted that G2019S shows elevated baseline RAB10 phosphorylation, but it’s unclear whether this represents true signal amplification during lysosomal swelling or just a higher activity floor. This distinction is crucial for understanding disease mechanisms and therapeutic targeting.\n\nSource: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867)”, “score”: 0.314, “reason”: “7 token overlaps; entity overlap: sda-2026-04-16-”, “analysis_id”: “SDA-2026-04-23-gap-debate-20260417-033119-54941818”, “quality_score”: 0.801, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}